CervoMed Director Joshua S. Boger acquired a significant stake in the company through a private placement, purchasing 955,414 units at a purchase price of $3.14 per unit. The transaction, completed on June 11, 2026, was executed by the Joshua S. Boger 2021 Trust DTD 12/09/2021, for which Boger serves as the sole trustee. This acquisition increases the director's exposure to the company's equity and derivatives.

Transaction Details

The private placement was conducted pursuant to a securities purchase agreement dated June 9, 2026. Each unit purchased comprises one share of common stock, one Series B warrant, and one Series C warrant. The Series B warrants carry an exercise price of $3.32 per share and are exercisable immediately, expiring five years from issuance. The Series C warrants have an exercise price of $3.14 per share, are also exercisable immediately, and expire one year from issuance.

Ownership and Limitations

Following the transaction, the Joshua S. Boger 2021 Trust holds 1,600,117 shares of common stock, while The Amy S. Boger 2021 Trust holds 195,748 shares. Boger serves as the sole trustee for both entities but disclaims beneficial ownership of these securities for Section 16 purposes. The warrants include a provision preventing the exercise of any portion that would cause the trust to beneficially own more than 19.99% of the outstanding common stock immediately thereafter.

CervoMed Inc., a clinical-stage biotechnology company developing treatments for age-related brain disorders, will participate in a fireside chat and one-on-one investor meetings at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit. The event is scheduled to take place virtually on Monday, June 15, 2026. This engagement provides investors with an opportunity to hear directly from management about the company's strategic direction and clinical progress.

Presentation Details

The fireside chat is set to occur from 7:00 AM to 7:30 AM ET. Investors can access the live webcast through a specific link provided for the event. Additionally, a recording of the session will be made available in the Investor section of the CervoMed website following the presentation.

Clinical Pipeline Overview

CervoMed's lead drug candidate, neflamapimod, is an oral small molecule designed to inhibit a key enzyme involved in neuroinflammation and neurodegeneration. The company recently completed the Phase 2b RewinD-LB trial evaluating neflamapimod in patients with Dementia with Lewy Bodies (DLB). In November 2025, CervoMed announced alignment with the FDA on a potential registration path for neflamapimod in DLB, though the initiation of a Phase 3 trial is subject to securing a partnership or additional financing.

Upcoming Milestones

The company has also completed enrollment in its ongoing Phase 2a clinical trial for neflamapimod in non-fluent variant primary progressive aphasia (nfvPPA), a subtype of frontotemporal disorders. Interim biomarker data from this trial is anticipated in the early fourth quarter of 2026. Furthermore, CervoMed expects the first patient to be dosed in the EXPERTS-ALS Phase 2a clinical trial during the fourth quarter of 2026.